Junshi Biosciences' Toripalimab Approved in China for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...

June 18, 2024 | Tuesday | News
AbbVie and FutureGen Announce Strategic Partnership to Develop Next-Generation IBD Therapy

AbbVie  and FutureGen Biopharmaceutical (Beijing) Co., Ltd. announced a license agreement to develop FG-M701, a next generation TL1A antibody for th...

June 14, 2024 | Friday | News
Bio-Thera's Biosimilar Bevacizumab Avzivi® Receives Positive CHMP Opinion, Moves Closer to European Approval

Bio-Thera Solutions , a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars,  announced th...

June 05, 2024 | Wednesday | News
InnoCare Pharma Completes Patient Enrollment for Phase II Trial of ICP-488, Advancing Novel Psoriasis Treatment

InnoCare Pharma,  a leading biopharmaceutical company dedicated to revolutionizing the treatment of cancer and autoimmune diseases, proudly announces ...

May 16, 2024 | Thursday | News
HUTCHMED Initiates Registrational Phase III Clinical Trial of HMPL-306 for Relapsed / Refractory Acute Myeloid Leukemia in China

  AML, a challenging hematological malignancy, often involves mutations of IDH1 and IDH2 enzymes, necessitating innovative treatment strategies. HMPL...

May 14, 2024 | Tuesday | News
Photocure's Partner Asieris Pharmaceuticals Advances Cevira® for Potential Approval in China

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National...

May 13, 2024 | Monday | News
ArcScan's Insight® 100 Granted NMPA Approval in China, Offering Advanced Solution for Myopia Treatment

ArcScan, Inc., a global medical technology company dedicated to helping ophthalmologists improve vision with ultra-high frequency ultrasound diagnostic ima...

May 13, 2024 | Monday | News
Zai Lab's AUGTYRO™ Approved by NMPA in China for ROS1-Positive NSCLC Treatment

Zai Lab Limited announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for AUGTYRO™ ...

May 13, 2024 | Monday | News
Ribobay Pharma and Cytiva Collaborate to Revolutionize Oligonucleotide Manufacturing

    Ribobay Pharma, a prominent Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO), in conjuncti...

May 09, 2024 | Thursday | News
Innovent Biologics Receives Breakthrough Therapy Designation for IBI343 in Advanced Gastric Cancer Treatment

Innovent Biologics a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncol...

May 07, 2024 | Tuesday | News
Avistone Biotechnology's Vebreltinib Granted Historic Approval for Glioma Treatment by Chinese NMPA, Paving the Way for Targeted Therapy Breakthroughs in 2024

Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision...

April 26, 2024 | Friday | News
Shanghai Junshi Biosciences' Toripalimab NDA Accepted by Hong Kong DO for Groundbreaking Nasopharyngeal Carcinoma Treatment

Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...

April 25, 2024 | Thursday | News
Innovent Biologics and HUTCHMED Announce Priority Review for Novel Combination Therapy in Advanced Endometrial Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

April 02, 2024 | Tuesday | News
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Incyte and China Medical System Holdings Limited  are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology m...

April 02, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in